Chiasma names Mark Fitzpatrick CEO
Mr. Fitzpatrick currently serves as Chiasma’s Chief Financial Officer. Mr. Fitzpatrick joined Chiasma as its Chief Financial Officer in June 2015 and has over 25 years of experience in the biotechnology industry.
He has held the senior-most financial leadership position and reported directly to the CEO of both public and private technology companies since 1991.
Prior to Aegerion, Mr. Fitzpatrick was vice president, CFO and assistant secretary at Proteon Therapeutics, Inc. and vice president and CFO, treasurer and assistant secretary at RenaMed Biologics, Inc.
He also held CFO positions with Dynogen Pharmaceuticals, WorldStreet Corporation and Diacrin. Mr. Fitzpatrick previously was a senior auditor with Arthur Andersen & Co.
He earned a Certified Public Accountant certificate in the Commonwealth of Massachusetts in 1987, and holds a B.S. in Accounting from Boston College.
He succeeds Mark Leuchtenberger, who has stepped down as Chief Executive Officer to pursue other opportunities. ■
LATEST MOVES FROM Massachusetts
- Chiasma re-appoints Roni Mamluk to board
- BayCoast Bank appoints James Wallace as CFO
- Pulmatrix appoints Amit D. Munshi to board
- Syros Pharmaceuticals appoints Srinivas Akkaraju to board
- Merrimack Pharma names Sergio Santillana as CMO
More inside POST
Ralph Lauren Q4 diluted EPS ($2.48) Earnings